June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Combination of intravitreal injection of Pegaptanib plus progressive PRP versus full PRP alone in patients with High Risk Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • Sérgio Leal
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
    CRIO / CHUC - Centro de Responsabilidade Integrado de Oftalmologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  • João Figueira
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
    CRIO / CHUC - Centro de Responsabilidade Integrado de Oftalmologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  • Luísa Ribeiro
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
  • Maria Luz Cachulo
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
    CRIO / CHUC - Centro de Responsabilidade Integrado de Oftalmologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  • Rufino Silva
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
    CRIO / CHUC - Centro de Responsabilidade Integrado de Oftalmologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  • Sandrina Nunes
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
  • Ana Pedroso
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
  • Miguel Costa
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
  • Jose Cunha-Vaz
    AIBILI - Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal
  • Footnotes
    Commercial Relationships Sérgio Leal, None; João Figueira, Alcon (C), Novartis (C), Allergan (C), Pfizer (C), Alimera (C), Bayer (C); Luísa Ribeiro, None; Maria Luz Cachulo, None; Rufino Silva, Thea (C), Novartis (C), Bayer (C), Allergan (C), Alimera (C); Sandrina Nunes, None; Ana Pedroso, None; Miguel Costa, None; Jose Cunha-Vaz, Allergan (C), Pfizer (C), Novartis (C), Alimera Sciences (C), Roche (C), Fovea Pharmaceuticals (C), Gene Signal (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2439. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sérgio Leal, João Figueira, Luísa Ribeiro, Maria Luz Cachulo, Rufino Silva, Sandrina Nunes, Ana Pedroso, Miguel Costa, Jose Cunha-Vaz; Combination of intravitreal injection of Pegaptanib plus progressive PRP versus full PRP alone in patients with High Risk Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2439.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate safety and efficacy of intravitreal (ITV) injection of pegaptanib combined with progressive panretinal photocoagulation (PRP) versus full PRP alone in the regression of retinal neovascularization in eyes with high-risk proliferative diabetic retinopathy (HR-PDR).

Methods: Twenty-two patients were included in a prospective, randomized, open label exploratory, phase II study to assess safety and efficacy of pegaptanib (0.3 mg ITV injections)+progressive PRP and full PRP alone in the treatment of patients with HR-PDR without previous laser treatment. Patients were randomized in a 1:1 ratio to one treatment arm: standard photocoagulation (PRP according the Diabetic Retinopathy Study; DRS), or combination treatment of pegaptanib ITV injections+progressive PRP (2 weeks±1 week after the first injection, starting with DRS third ring, extending from the ora serrata to the mid-periphery with coalescing spots followed, if needed, by the DRS second and first ring). One eye was selected and treated as the study eye. Patients underwent at baseline, months 3, 6 and 12: Best Corrected Visual Acuity (BCVA), Color Fundus Photography (CFP), Fluorescein Angiography (FA), Spectral Domain Optical Coherence Tomography (SD-OCT) and Visual Fields (VF). Retinal neovascularization (NV) was measured in disc area units based on CFP and/or FA.

Results: 20 patients completed the first 6 months of follow-up (16 males and 4 females). Age ranged from 38 to 76 (mean±SD: 54.8±9.9 years). Mean HbA1C was 7.9±1.5% and the systolic and diastolic blood pressure was respectively of 142.4±11.1 and 79.7±6.3 mmHg. From baseline to month-6, in the pegaptanib+ PRP group the BCVA decreased less (PRP: 77.8±8.4 to 71.6±15.7, P=0.075; pegaptanib+PRP: 69.0±15.6 to 68.1±20.9, P=0.651); RT showed a lower increase (PRP: 321.1±151.4 to 394.0±183.9, P=0.012; pegaptanib+PRP: 411.1±190.7 to 479.3±252.4, P=0.327); and VF was better maintained (PRP: 37.8±18.4 to 31.7±19.7, P=0.044; pegaptanib+PRP: 28.6±16.8 to 27.1±18.5, P=0.202). NV regression was similar in both groups (PRP: 3.1±4.9 to 2.6±3.5, P=0.678; pegaptanib+PRP: 3.2±2.7 to 2.5±2.7, P=0.213).

Conclusions: The association of ITV pegaptanib with progressive PRP showed at 6-months better preservation of BCVA, lower increase in RT and better maintained VF than full PRP alone, but without major differences in NV regression.

Keywords: 688 retina • 499 diabetic retinopathy • 550 imaging/image analysis: clinical  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×